Pramipexol retard is the newest drug for the treatment of Parkinson's disease. The prolonged release of the agent in this preparation allows a more continuous dopaminergic stimulation than previous preparations, without reducing the agent's already known and proven clinical efficiency. In addition, it has a more favourable adverse effect profile than previous preparations, and patient compliance can also be better as it needs to be taken only once daily. These benefits have been proven in recent clinical studies, of which the most important ones are reviewed here.
|Translated title of the contribution||Clinical studies on pramipexol retard|
|Number of pages||4|
|Publication status||Published - May 30 2010|
ASJC Scopus subject areas
- Clinical Neurology